Guardian Approval Should Give Medtronic Sizable Lead In CGMS Market
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of Medtronic's Guardian continuous glucose monitoring system gives the firm a headstart on primary competitor TheraSense's FreeStyle Navigator CGMS
You may also be interested in...
Medtronic’s Guardian “Real-Time” Glucose Monitor Receives FDA Approval
FDA approval of the Guardian RT continuous glucose monitoring system bodes well for the regulatory success of an integrated insulin pump-glucose monitoring product, Medtronic says
Medtronic’s Guardian “Real-Time” Glucose Monitor Receives FDA Approval
FDA approval of the Guardian RT continuous glucose monitoring system bodes well for the regulatory success of an integrated insulin pump-glucose monitoring product, Medtronic says
DexCom IPO Assists Firm In Quest For Next-Generation CGMS Approval
DexCom will use part of the $54.9 mil. in net proceeds it expects to garner from an April 14 initial public offering to support ongoing clinical trials for its two continuous blood glucose monitoring systems